NCT02511613View on ClinicalTrials.gov

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Squalamine Lactate Ophthalmic Solution, 0.2%

Squalamine Lactate Ophthalmic Solution, 0.2% administered BID

DRUG

Placebo Ophthalmic Solution

Placebo Ophthalmic Solution, administered BID

DRUG

ranibizumab

ranibizumab intravitreal injection

Trial Locations (4)

10022

Investigational Site, New York

21740

Investigational Site, Hagerstown

77030

Investigational Site, Houston

90211

Investigational Site, Beverly Hills

Sponsors
All Listed Sponsors
lead

Ohr Pharmaceutical Inc.

INDUSTRY